12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Isentress raltegravir regulatory update

Merck said FDA approved an updated label for Isentress raltegravir to include 3-year data from the 5-year, double-blind Phase III STARTMRK trial of the HIV drug in combination therapy in...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >